MacroGenics, Inc. (MGNX)
MacroGenics, Inc. is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for cancer and autoimmune diseases. The company leverages its proprietary protein engineering platform to create targeted treatments aimed at enhancing immune responses and improving patient outcomes.
Company News
MacroGenics reported Q2 2025 financial results with revenue of $22.2 million, missing analyst expectations. The company is focusing on its research-stage pipeline and strategic partnerships while managing costs after exiting its previous marketed product.
Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of MacroGenics, Apellis Pharmaceuticals, Teradata, and Maplebear. The investigations are related to alleged false and misleading statements made by the companies.
Analysts' ratings for Macrogenics (NASDAQ:MGNX) over the last quarter vary from bullish to bearish, as provided by 14 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bear...
MacroGenics (MGNX) delivered earnings and revenue surprises of -188.46% and 58.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?